Aandeel 1ZL ZAI LAB LIMITED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Zai Lab Limited Börse Stuttgart

Aandelen

1ZL

US98887Q1040

Beurs gesloten - Börse Stuttgart
Andere beurzen
 08:06:52 05-07-2024 		Nabeurs 22:00:01
15,6 EUR 0,00% Intraday-grafiek van Zai Lab Limited 15,95 +2,24%
27/06 Insider van Zai Lab verkocht aandelen ter waarde van $428.532, volgens een recent SEC-document MT
20/06 Zai Lab kent ADS's toe aan onafhankelijke bestuurders onder stimuleringsplan MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ZLAB
  4. Koers 1ZL
  5. Nieuws Zai Lab Limited
  6. Andere talen